Latest Zidovudine Stories

Patients to benefit from potential for improved efficacy in less commonly used types of ARV therapies and one-pill-daily combination drugs LONDON, April 17, 2013 /PRNewswire/ -- The anticipated launch of drugs currently in the pipeline, together with the introduction of oral combination pills, are set to have a profound impact on the European HIV drugs market. New analysis from Frost & Sullivan (http://www.lifesciences.frost.com), Analysis of the European HIV Drugs Market, finds...

Antiretroviral therapy does not affect resting energy expenditure among women with HIV, according to Journal of the Academy of Nutrition and Dietetics report Studies have shown that about 10 percent of men infected with human immunodeficiency virus (HIV) have an elevated resting energy expenditure (REE). Their bodies use more kilocalories for basic functions including circulation, body temperature, and breathing. Most studies have been conducted in men and those with solely women have had...

In South Africa, people with HIV who start treatment with anti-AIDS drugs (antiretroviral therapy) have life expectancies around 80% of that of the general population provided that they start treatment before their CD4 count drops below 200 (cells per microliter), according to a study by South African researchers published in this week's PLOS Medicine. These findings are encouraging and show that with long-term treatment, HIV can be managed as a chronic illness in middle- and low-income...

redOrbit Staff & Wire Reports – Your Universe Online Administering early treatment shortly after HIV infection could lead to a so-called functional cure in approximately one out of every 10 patients infected with the virus that causes AIDS, according to a new study published in the journal PLoS Pathogens. Lead researcher Asier Sáez-Cirión of the Institut Pasteur in Paris and colleagues discovered that 14 patients who were treated within the first two months following infection...

BETHESDA, Md., March 12, 2013 /PRNewswire/ -- Providing life-long antiretroviral treatment to HIV-infected pregnant women not only prevents HIV infections in infants, but also improves the 10-year survival rate in mothers, saving more than 250,000 maternal life years and reducing the likelihood that children born to these mothers will become orphans, a study published today in the journal PLOS ONE found. Transmission of HIV during pregnancy, labor, delivery or breastfeeding is the...

Multi-site study, led by a Miriam Hospital researcher, could change treatment strategy for these patients A new multi-site study reveals patients with drug-resistant HIV can safely achieve viral suppression – the primary goal of HIV therapy – without incorporating the traditional class of HIV medications into their treatment regimen. Karen Tashima, M.D., director of the HIV Clinical Trials Program at The Miriam Hospital, served as study chair. The AIDS Clinical Trials Group (ACTG)...

Lawrence LeBlond for redOrbit.com - Your Universe Online AIDS research has come a long way since the disease was first clinically discovered in 1981 and officially named by the US Centers for Disease Control and Prevention (CDC) in 1982. And although many hurdles had been overcome in the prevention and treatment of the world’s deadliest sexually-transmitted infection (STI) over the past thirty years, no real cure had ever been found. That is until today. Unveiling their landmark...

Alere Pima™ CD4 test provides point-of-care HIV health status in under 20 minutes Waltham, Massachusetts (PRWEB) February 09, 2013 Alere Inc. is pleased to announce that, with the aid of a revolutionary point-of-care device, World Health Clinicians, a US-based nongovernmental organization, were able to provide absolute CD4 counts for patients living with HIV in rural Zimbabwe in under 20 minutes. This outcome is the result of a proof-of-concept evaluation World Health Clinicians...

A 48-week course of antiretroviral medication taken in the early stages of HIV infection slows the damage to the immune system and delays the need for long term treatment, according to research published today in the New England Journal of Medicine. However, the delay was only marginally longer than the time already spent on treatment. The study, the largest clinical trial ever undertaken looking at treating people with recent HIV infection, also suggests that the treatment lowers the...

Earlier therapy enhances restoration of CD4+ T-cell counts Patients who are started on antiretroviral therapy for HIV-1 infection within four months of estimated infection date — and who have higher counts of CD4+ T-cells at the initiation of therapy — demonstrate a stronger recovery of CD4+ T-cell counts than patients in whom therapy is started later, a new study shows. The report, to be published Thursday in The New England Journal of Medicine, is co-authored by physicians of UT...